Interpreting IDeate-Lung02 Trial Outcomes

Opinion
Video

Joshua K. Sabari, MD, discusses the efficacy outcomes from the Ideate-Lung02 trial, noting the 52.4% ORR, 5.9-month median DOR, and 12.2-month OS and emphasizing that a 12-month OS is clinically meaningful for this patient population following a median of 2 prior lines of therapy.

Video content above is prompted by the following:

Please share your impressions of the efficacy outcomes reported in Ideate-Lung02: a 52.4% ORR, a 5.9-month median DOR, and a 12.2-month OS.
• How clinically meaningful do you consider a 12-month OS in this study population after a median of 2 prior lines of therapy?

Recent Videos
Related Content